Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: Results of a phase II trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 2, 2008, Pages 157-162

  Dragovich, Tomislav ^a,d   Burris III, Howard ^b   Loehrer, Patrick ^c   Von Hoff, Daniel D ^a   Chow, Sherry ^a   Stratton, Steven ^a   Green, Sylvan ^a   Obregon, Yrma ^a   Alvarez, Irene ^a   Gordon, Michael ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Celecoxib; COX 2 (cycloxygenase 2); Gemcitabine; Pancreatic adenocarcinoma; Phase II trial; VEGF (vascular endothelial growth factor)

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; GEMCITABINE; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LOW DRUG DOSE; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42049123958     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815878c9     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
4. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
5. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR] versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E601). Proc Am Soc Clin Oncol. 2006;24(18S):Abstr.
6. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
7. Heinemann V, Quietzsch D, Giesleler F, et al. A Phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol. 2003;1003:250abstr.
8. Rocha Lima C, Rotche R, Jeffery M. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. ASCO Annual Meeting Proc. 2003;22:251.
9. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer. 2005;(suppl 4): PS 11 Abstr.
10. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol. 2004;5:541-549.
11. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Annual Meeting Proc. 2005;23:1s.
12. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin Oncol. 2007;25(18S):Abstr.
13. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine (G) plus Cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study. J Clin Oncol. 2007; ASCO Annual Meeting Proc. Part I. 25(18S): LBA4509.
14. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990.
15. Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol. 2004;54(Suppl 1):S69-S77.
16. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002;62:625-631.
17. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res. 2003;37:179-192.
18. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952.
19. Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 2004;64:2030-2038.
20. Raut CP, Nawrocki S, Lashinger LM, et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther. 2004;3:1217-1224.
21. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
22. Therasse P, Arbuck SG, Eosemjaier EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
23. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
24. Xiong HQ, Du M, Wolff RA, et al. A pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Cancer Chemother Pharmacol. 2005;55:559-564.
25. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
26. Jimeno A, Amador ML, Kulesza P, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther. 2006;5:3240-3247.
27. Reckamp KL, Krysan K, Morrow JD, et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006;12:3381-3388.